In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Clicks: 259
ID: 266176
2020
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Hydroxychloroquine was found to be more potent than chloroquine at inhibiting SARS-CoV-2 in vitro. Hydroxychloroquine sulfate 400 mg given twice daily for 1 day
Reference Key
xueting2020clinicalin Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yao, Xueting;Ye, Fei;Zhang, Miao;Cui, Cheng;Huang, Baoying;Niu, Peihua;Liu, Xu;Zhao, Li;Dong, Erdan;Song, Chunli;Zhan, Siyan;Lu, Roujian;Li, Haiyan;Tan, Wenjie;Liu, Dongyang;
Journal clinical infectious diseases
Year 2020
DOI
DOI not found
URL
https://academic.oup.com/cid/article/71/15/732/5801998
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE covid-19 sars-cov-2 animals pubmed abstract nih national institutes of health national library of medicine pandemics research support non-u.s. gov't cell line pneumonia viral / drug therapy* chlorocebus aethiops vero cells antiviral agents / pharmacology* lung / drug effects betacoronavirus / drug effects* coronavirus infections / drug therapy* pmid:32150618 pmc7108130 doi:10.1093/cid/ciaa237 xueting yao fei ye dongyang liu antiviral agents / pharmacokinetics chloroquine / pharmacokinetics chloroquine / pharmacology hydroxychloroquine / pharmacokinetics hydroxychloroquine / pharmacology* severe acute respiratory syndrome / drug therapy*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.